Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Award of licensing option in the North Celtic Sea

3 May 2013 07:00

RNS Number : 9277D
Fastnet Oil & Gas PLC
03 May 2013
 



3 May 2013

Fastnet Oil & Gas Plc

Award of new licensing option in the North Celtic Sea

 

Fastnet Oil & Gas Plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI) the E&P company focused on near term exploration acreage in Africa and the Celtic Sea is pleased to announce that it has been notified by the Irish Department of Communications, Energy and Natural Resources (the "Department") that it has been awarded licensing option 13/3 over part blocks 56/6, 56/7, 56/8, 56/9, 56/11, 56/12, 56/13 and 56/14 in the Mizzen Basin ("East Mizzen") and the western end of the North Celtic Sea Basin, offshore Ireland ("East Mizzen Licensing Option"). The newly named East Mizzen Licensing Option is valid from 1 May 2013 until 30 September 2014. It covers an area of 1,155 sq. km., and is contiguous with and extending eastwards from the previously awarded Mizzen Licensing Option 12/3, announced on 12 June 2012. Fastnet is the designated operator and has a 100% working interest in the East Mizzen Licensing Option.

 

Highlights

§ 18 month licensing option requiring the reprocessing of a minimum of 400 km. of existing 2D seismic data and the carrying out of various desktop studies

 

§ Potential to extend the East Mizzen Licensing Option by a further 18 months subject to a satisfactory work programme being agreed with the Department

 

§ Light oil shows encountered in basal Cretaceous sands, analogous to the Barryroe tested interval, in the 56/12-1 well drilled off-structure by Esso/Marathon in 1975

 

§ Value-enhancing 3D seismic being acquired at no additional cost to Fastnet's current programme to define updip drilling locations

 

§ Farmout process alreadyunderway with significant industry interest in the Mizzen and East Mizzen portfolio of prospective structures

 

Details of the East Mizzen Licensing Option

The East Mizzen Licensing Option acreage lies in water depths of up to 130 metres in the Mizzen Basin and southwest part of the North Celtic Sea Basin. Esso/Marathon drilled the 56/12-1 well in 1975 in East Mizzen based on a sparse grid of poor quality 2D seismic data. It was located to test large structural closures at the Base Chalk, Base Kimmeridgian unconformity and within the Lower Jurassic and Triassic. The well was drilled to 8,773 feet but failed to reach the base of the Cretaceous. Analysis of dipmeter data for the well and 2D seismic acquired much later after the well was drilled indicates that the well was drilled off-structure. Two large structural culminations are mapped to the northwest and east of the well which may be prospective for the same basal Cretaceous sands that were encountered in the well. In the well light oil shows were present near the base of the Cretaceous. Geochemical analysis suggests that the oil was sourced from the same Upper Jurassic source rocks that have sourced the Barryroe oil accumulation, which was successfully flow-tested by Marathon (1990) and Providence (2012).

The area of the East Mizzen Licensing Option is also favourably located for the development of prospective Triassic reservoirs sealed by salt. A number of structural leads have been identified by Fastnet along this trend based on existing 2D seismic data. The Board is of the view that the geological setting of these structures is analogous to that for the Wytch Farm oil field in southern England.

 

Work program

Fastnet has committed to a work programme for the initial 18 month period of the East Mizzen Licensing Option (the "Initial Phase") which is to reprocess a minimum of 400 km. of existing 2D seismic data and to undertake desktop studies.

Subject to the results of the work programme in the Initial Phase, Fastnet has the option to agree a further work program with the Department to acquire 3D seismic data during an 18 month extension to the Initial Phase in order to better define the size of the traps tested by the wells.

Fastnet is already in the process of acquiring 3D seismic over Deep Kinsale and acquisition is planned to commence on the Mizzen Licensing Option in the North Celtic Sea. The undershoot of the Kinsale platforms has been successfully completed under budget. Following the completion of the remaining 3D seismic programme over Deep Kinsale the seismic vessel is to transit to the Mizzen and East Mizzen Licensing Option areas to acquire a contiguous 1,200 sq. km. of 3D seismic data. Funding for that part of the programme covering East Mizzen has already been included in Fastnet's previously announced estimate for the cost of the Celtic Sea 3D seismic program and therefore the inclusion of East Mizzen will not result in any additional cost.

 The opportunity to fast-track the acquisition of 3D seismic in East Mizzen in the Initial Phase of the East Mizzen Licensing Option will allow Fastnet to de-risk and mature multiple prospects for drilling over Fastnet's licensed Mizzen acreage covering 1,942 sq. km., approximately equivalent to tenNorth Sea blocks.

 

Paul Griffiths, Managing Director of Fastnet commented:

"We are delighted to have added to our inventory of material prospective structures in the Mizzen area offshore Ireland. This has allowed us to capitalise on the interest being shown by the industry in our farmout process in this particularly under-explored, yet highly prospective, basin. It has also allowed us to maximise the value of our on-going 3D seismic acquisition by creating "running room" for potential farminees that have identified the Mizzen Basin as a new emerging shallow water exploration province offshore Ireland. Fastnet is one of the largest acreage holders in this area contributing to creating the conditions necessary to develop competition for acreage in an area that previously lacked industry focus. This situation mirrors our 'first mover' strategy in Morocco."

 

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

 

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

Corporate Broking

Jerry Keen

 

+44 (0) 20 7408 4090

 

Mirabaud Securities LLP

(Joint Broker)

Peter Krens, Edward Haig-Thomas

 

+44 (20) 7321 2508

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

 

+353 (1) 679 6363

 

FTI Consulting

Edward Westropp, Natalia Erikssen, Jess Allum

 

+44 (0) 207 831 3113

 

Notes to editors

Fastnet Oil & Gas plc is an independent oil and gas exploration company that focuses on identifying early stage exploration and appraisal opportunities in Offshore Ireland and Africa. It is quoted on the AIM market of the London Stock Exchange and the Enterprise Securities Market ("ESM") of the Irish Stock Exchange. Fastnet's aim is to assemble a portfolio of high impact conventional oil and gas assets that will deliver sustainable growth and value for the Company. Its immediate focus is on implementing its Offshore Ireland and Africa strategies where it has been awarded four offshore licensing options in the Celtic Sea (Molly Malone Basin, Shanagarry, 49/13 and Mizzen Basin) and acquired a material interest in the highly prospective Foum Assaka permit Offshore Morocco. In addition, Fastnet will continue to pursue new conventional oil and gas opportunities in Africa where the Directors and Advisory Board also have extensive knowledge, contacts and experience of creating value.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEBLGDUISGBGXD
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.